0.78
-0.0257(-3.21%)
Currency In USD
| Previous Close | 0.8 |
| Open | 0.77 |
| Day High | 0.82 |
| Day Low | 0.75 |
| 52-Week High | 4.32 |
| 52-Week Low | 0.6 |
| Volume | 280,418 |
| Average Volume | 2.2M |
| Market Cap | 7.07M |
| PE | -0.21 |
| EPS | -3.64 |
| Moving Average 50 Days | 0.82 |
| Moving Average 200 Days | 1.2 |
| Change | -0.03 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of August 20, 2025 at a share price of $0.775. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.24 as of August 20, 2025 at a share price of $0.775.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
GlobeNewswire Inc.
Aug 07, 2025 1:15 PM GMT
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Colon tissu
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
GlobeNewswire Inc.
Jul 31, 2025 12:45 PM GMT
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs Inflammatory Bowel Disease is a large and grow
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
GlobeNewswire Inc.
Jul 24, 2025 12:00 AM GMT
Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune,